Clinical trials: Drug-Resistant Focal Epilepsy
Drug Resistant Epilepsy, Epilepsy
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure
- Trial name
- NCT06388707
- Testing
- NaviFUS System
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NaviFUS Corporation
Epilepsy, Drug Resistant
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor…
- Trial name
- STEM (NCT06248333)
- Testing
- STN-DBS ON, STN-DBS OFF
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xuanwu Hospital, Beijing
Epilepsy, Dravet Syndrome
A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome
Dravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodium channels.
- Conditions
- Epilepsy, Dravet Syndrome, Drug Resistant Epilepsy, Healthy Controls
- Trial name
- DRAPETONINE (NCT07013331)
- Testing
- [18F]MPPF PET-MRI
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Partial Epilepsy
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
Epilepsy is the most common chronic neurological disorder in the world, affecting more than 50 million people worldwide. Approximately 35% of patients with epilepsy are refractory to all available antiepileptic drugs.
- Trial name
- EPIMAGE (NCT01735032)
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Mesial Temporal Lobe Epilepsy
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe…
- Trial name
- EPIC (NCT05135091)
- Testing
- NRTX-1001
- Where
- 36 sites in United States
- Volunteers
- 88 people
- Sponsor
- Neurona Therapeutics
Drug Resistant Epilepsy
Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial
The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe…
- Trial name
- LIFUS (NCT03868293)
- Testing
- Focused ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Drug Resistant Epilepsy, Seizure
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
To evaluate the safety and efficacy of using NaviFUS™ system in patients with drug resistant epilepsy
- Conditions
- Drug Resistant Epilepsy, Seizure, Seizure Disorder, Epilepsy
- Trial name
- NCT04999046
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- NaviFUS Corporation
Drug-resistant Epilepsy, Focal-Onset Seizures
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset…
- Trial name
- ARISE (NCT03373383)
- Testing
- Padsevonil
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 411 people
- Sponsor
- UCB Biopharma S.P.R.L.
Focal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 2 (NCT06132893)
- Testing
- BHV-7000
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Drug-Resistant Focal Epilepsy
Temporal Interference Brain Stimulation for Adults With Drug-Resistant Epilepsy Undergoing Stereo-EEG Monitoring
This study evaluates whether a non-invasive brain stimulation technique called Temporal Interference (TI) can reduce epilepsy-related abnormal brain activity and influence sleep-related brain rhythms in adults with focal…
- Trial name
- NCT07764718
- Testing
- Temporal Interference Stimulation, Direct Electrical Stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Refractory Epilepsy, Focal Epilepsy
Atlas of Human Cognition by SEEG (MAPCOG-SEEG)
The main objective of MAPCOG_SEEG is to create a database including brain recordings of cognition performed in clinical routine in patients during the pre-surgical SEEG assessment.
- Trial name
- MAPCOG-SEEG (NCT03644732)
- Testing
- SEEG Group
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Grenoble
Epilepsy, Drug Resistant
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive…
- Trial name
- NCT07095933
- Testing
- Everolimus
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xuanwu Hospital, Beijing
Epilepsy, Partial
An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy
observational, non-interventional study in 120 patients with drug-resistant partial epilepsy, comprising two phases: a 3-month retrospective and a 6-month prospective.
- Trial name
- NCT01332539
- Testing
- no intervention
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Intractable Epilepsy, Malignant Glioma
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures.
- Conditions
- Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma
- Trial name
- NCT04650204
- Testing
- Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Epilepsy, Seizures, Epileptic
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
- Trial name
- NCT05518578
- Testing
- SPN-817
- Where
- 10 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
Evaluation of Direct Effects of Electric Fields on Brain
Transcranial current stimulation (tCS), a safe, tolerable technique employing weak currents (~ 1 mA) applied to the scalp, has been shown to be a promising technique in alleviating seizures in focal epilepsy patients.
- Trial name
- GALVANI PS-2 (NCT05250713)
- Testing
- Transcranial stimulation
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Epilepsy, Epilepsy, Focal
MELD as an Adjunct for SEEG Trajectories
Epilepsy is a disorder of the brain which is associated with disabling seizures and affects 100,000 people under 25. Many children with epilepsy also have a learning disability or problems with development.
- Conditions
- Epilepsy, Epilepsy, Focal, Epilepsy, Refractory
- Trial name
- MAST (NCT04383028)
- Testing
- MELD algorithm use to aid in the planning of SEEG electrode trajectories
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust